Chronic thromboembolic pulmonary hypertension (CTEPH) is responsible for significant levels of morbidity and mortality. The estimated cumulative incidence of CTEPH is 2-4% among patients presenting with acute pulmonary thromboembolism. Currently, at the time of CTEPH diagnosis, 37.9% of the patients in an international registry were receiving at least one pulmonary arterial hypertension (PAH)-targeted therapy. Advanced medical therapy is considered in patients with inoperable disease, as a bridge to pulmonary endarterectomy or in those with persistent or recurrent pulmonary hypertension. PAH-specific medical therapies include endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogues. The present article will focus on recent developments in the pharmacological treatment of CTEPH.
Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of pulmonary thromboembolism (PTE). CTEPH is a rare complication of PTE; however, it is associated with significant rates of mortality and morbidity. The three-year mortality was reported as 90% in the patients with PAP > 50 mmHg. [1] CTEPH is included in Group IV according to the 2008 Dana Point Classification. [2] The CTEPH incidence after the first PTE episode varies between 2% and 4%. [3, 4] The incidence of CTEPH was 4.6% in our study, which followed 325 patients for a mean duration of 16.3 months at our center. [5] Interestingly, the majority of the subjects diagnosed with CTEPH did not have a previous PTE diagnosis. [6, 7] Currently, available data demonstrate the frequency of CTEPH in the symptomatic patients and suggest that the rate is actually higher when considering the asymptomatic and unscreened patients.
The present review discusses the pharmacological treatment of CTEPH in light of the current literature. The review will particularly focus on the outcomes obtained in CTEPH with specific medical treatments (prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors) used in idiopathic pulmonary arterial hypertension (IPAH).
DIAGNOSIS
CTEPH should be considered in patients with an mPAP ≥ 25 mmHg in echocardiography and unexplained dyspnea and/or previous PTE history (in the preceding six months or more). It should be kept in mind that the risk of developing CTEPH is particularly high in patients with certain risk factors (e.g., recurrent PTE, splenectomy, lupus anticoagulant, or antiphospholipid antibodies). [8] Computed tomography pulmonary angiography or ventilation perfusion scan should be performed for definitive diagnosis in these patients. Subsequently, right heart catheterization should be performed in order to confirm the diagnosis of pulmonary hypertension (PH) and to demonstrate the hemodynamic state. The treatment decision should be planned with a multidisciplinary approach (including chest diseases, cardiology, cardiovascular surgery, and radiology).
TREATMENT APPROACH
The primary treatment is pulmonary thromboendarterectomy (PEA) in the patients diagnosed with CTEPH. PEA indications are 1) New York Heart Association (NYHA) Functional Class III or IV; 2) pulmonary vascular resistance (PVR) higher than 300 dyn.s/cm 5 prior to surgery; 3) surgically accessible thrombi in main, lobar, or segmental pulmonary arteries; and 4) absence of other concomitant severe conditions. [2] However, approximately 20-40% of CTEPH patients are considered inoperable. [11, 12] In patients with an mPAP < 40 mmHg and an mPAP >50 mmHg in whom PEA is not performed, five-year survival was reported as 30% and 10%, respectively. [13, 14] The major vessel obstruction and remodeling combined with small vessel arteriopathy in CTEPH were shown to be histologically indistinguishable from the classical arteriopathy observed in pulmonary arterial hypertension (PAH). Therefore, PAH-specific treatment may be used in patients with CTEPH due to the morphological changes resembling IPAH. [15] Currently, 37.9% of CTEPH patients are reported as receiving PAH-specific treatments. [16] Medical treatment is recommended for four patient groups in CTEPH: (1) Patients ineligible for endarterectomy due to distal thrombus (segmental, subsegmental); (2) prior to PEA; (3) persistent PH following PEA; and (4) patients in whom PEA in contraindicated due to concomitant comorbid conditions (severe pulmonary parenchymal disease, morbid obesity, hepatic or renal dysfunction, diabetes mellitus, and coronary artery disease). [15] Additionally, the patients in whom a decrease less than 50% is expected in pulmonary vascular resistance following PEA and the patients with PVR > 1,200 dyn.s/cm 5 are also considered ineligible for PEA. [12] A study reported mortality rates as 4%, 10%, and 20% in the patients with PVR <900 dyn.s/cm 5 , PVR = 900-1200 dyn.s/cm 5 , and PVR >1,200 dyn.s/cm 5 , respectively. [10] Standard medical treatment of CTEPH consists of diuretics, oxygen therapy, and life-long anticoagulant therapy. [17] The target of anticoagulant therapy should be an international normalized ratio of 2-3. Anticoagulant therapy prevents in situ pulmonary artery thrombosis and recurrent thromboembolism. [18] Long-term anticoagulant therapy was shown to reduce the risk of recurrent thromboembolism, particularly in patients with idiopathic or unprovoked pulmonary embolism. [19, 20] In a small study including 10 patients with an mPAP below 30 mmHg who were receiving oral anticoagulant therapy, the functional capacity (FC) was shown to reduce from II to I over three years. [21] PAH-SPECIFIC TREATMENTS
Treatment of inoperable patients
In the BENEFIT (Bosentan Effects in iNopErable Forms of CTEPH) study comparing a total of 157 patients with CTEPH (80 patients on placebo and 77 patients on bosentan) for 16 weeks, PVR and cardiac index (CI) were improved, while no difference was found in 6-Minute Walk Distance test (6MWD) and FC. [22] In a study evaluating 104 patients (76 patients with FC III) by using high doses (3 × 50 mg) sildenafil, notable improvement was detected in PVR, CI, 6MWD, and FC. The increase of 51 m in 6MWD over three months was observed to be maintained for 12 months. [23] In a randomized, double-blind, placebo-controlled study including 19 inoperable patients with CTEPH, using sildenafil, an increase of 36 (8-64) m was found in 6MWD over 12 months. Again, a 19% decrease was determined in NT-proBNP levels compared to baseline. [24] Olchewski et al. [25] conducted a placebo-controlled study with iloprost in a total of 203 patients (57 inoperable CTEPH patients). This 12-week study, also known as the Aerosolized Iloprost Randomized study, also demonstrated significant improvement in PVR, 6MWD, and cardiac output. One of the important results of this study was the two-fold increase observed in 6MWD in the IPAH group compared to patients with CTEPH. 2 ) were shown to decrease, while a significant improvement (an increase of 66 m) was demonstrated in 6MWD over three months. The one-year, two-year, and three-year survival rates were found as 73%, 59%, and 41%, respectively. [26] A single-center, uncontrolled observational study was conducted with subcutaneous treprostinil in 28 inoperable patients with severe CTEPH. Catheterization was performed over 19 ± 6.3 months for the 19 patients under follow-up. Treprostinil provided a notable improvement in PVR. The five-year survival was 53% in the group receiving treprostinil versus 16% in the untreated group. [27] Pre-PEA treatment
The majority of the patients' candidate for preoperative PEA is hemodynamically instable in the perioperative period, therefore causing an increased surgical risk. Patients in NYHA Class IV, those with an mPAP > 50 mmHg, patients with a CI < 2.0 L/min/m 2 , and those with PVR > 1,000 dyn.s/cm 5 are defined as patients at high preoperative risk. In such patients with CTEPH, medical treatment improves preoperative pulmonary hemodynamics and increases surgical success. [15] In a study with 33 patients (21 patients with PVR < 1,200), 12 patients received ıntravenous prostacyclin, and pre-PEA medical treatment was administered to 21 patients. This study showed a significant decrease in PVR (pretreatment: 1.510 ± 53, post-treatment: 1,088 ± 58 dyn.s/cm
5
; P < 0.001) and plasma BNP levels (pretreatment: 547 ± 112, post-treatment; 188 ± 30 pg/mL; P < 0.01) in the pre-PEA prostacyclin. Group 1 patients (8.3%) in the prostacyclin group died due to severe CTEPH during the perioperative period. The time from medical treatment to PEA was reported as 46 ± 12 days, and the mean prostacyclin dose was reported as 6 ± 1 ng/kg/min in this study. [28] In a retrospective study, Jensen et al. [29] demonstrated that preoperative treatment provided minimal improvement in hemodynamics and caused delays regarding surgery. Therefore, administration of preoperative medical treatment should not delay the surgical process of the patient. Another important issue is the fact that the duration of medical treatment to be administered prior to surgery is not clear in these patients. [15] Post-PEA treatment Persistent PH was demonstrated in approximately 10-15% of post-PEA patients. [30] In particular, distal vasculopathy with morphological changes similar to IPAH, also known as "Class IV CTEPH," was shown in CTEPH patients developing persistent PH in the post-PEA period. [10] Therefore, specific treatments are suggested to be effective in this patient group. There are limited data in literature regarding the use of medical treatment in patients with postsurgical persistent PH. A total of 469 patients were included in a multicenter, prospective, observational study where 236 patients had PEA and 148 patients received medical treatment as they were ineligible for surgery due to distal thrombus. In this study, persistent PH was defined as mPAP ≥ 25 mmHg and PVR > 240 dyn.s/cm
. Persistent PH developed in 70 (35%) patients during the postoperative period. Medical treatment was added for patients with PAB ≥ 30 mmHg. At the end of two years, 18% of the patients who underwent surgery had received medical treatment. Survival at one to three years in the surgical group was found as 88-76%, respectively; and as 82-70% in the medical group, respectively (P = 0.023). However, the functional improvement achieved in three months in the medical group was not maintained in Year 2. [31] Kramm et al. [32] conducted another placebo-controlled study with 22 patients and demonstrated substantial improvement in hemodynamic parameters (mPAP, PVR, and decreased Right Ventricle afterload and increased CI) of the patients who received iloprost following PEA.
Riociguat, an oral, soluble guanylate cyclase stimulator affecting the nitric oxide receptor has been studied in patients with CTEPH. [33] Inoperable patients with CTEPH (42 patients) and PAH (33 patients) with FC II-III were included and followed for 12 weeks in a multicenter Phase II study. Patients with CTEPH showed an increase of 55.0 m while patients with PAH showed an increase of 57.0 m in 6MWD, showing a statistically significant difference compared to baseline. In this study, 56% of the patients experienced adverse events and these side effects resulted in discontinuation of the drug in 4% of the patients. The most common side effects were reported as dyspepsia, headache, and hypotension. [34] CONCLUSION Currently, studies on the use of PAH-specific treatments in patients with CTEPH are retrospective and nonrandomized studies conducted in heterogeneous patient groups. There is no specific medical treatment currently approved for CTEPH. PEA remains as the main and curative treatment in CTEPH. However, PAH-specific treatments should be considered in patients ineligible for PEA.
